Cargando…
Chimeric aptamers in cancer cell-targeted drug delivery
Aptamers are single-stranded structured oligonucleotides (DNA or RNA) that can bind to a wide range of targets ("apatopes") with high affinity and specificity. These nucleic acid ligands, generated from pools of random-sequence by an in vitro selection process referred to as systematic evo...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Informa Healthcare
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3233271/ https://www.ncbi.nlm.nih.gov/pubmed/21955150 http://dx.doi.org/10.3109/10409238.2011.614592 |
_version_ | 1782218392683413504 |
---|---|
author | Kanwar, Jagat R Roy, Kislay Kanwar, Rupinder K |
author_facet | Kanwar, Jagat R Roy, Kislay Kanwar, Rupinder K |
author_sort | Kanwar, Jagat R |
collection | PubMed |
description | Aptamers are single-stranded structured oligonucleotides (DNA or RNA) that can bind to a wide range of targets ("apatopes") with high affinity and specificity. These nucleic acid ligands, generated from pools of random-sequence by an in vitro selection process referred to as systematic evolution of ligands by exponential enrichment (SELEX), have now been identified as excellent tools for chemical biology, therapeutic delivery, diagnosis, research, and monitoring therapy in real-time imaging. Today, aptamers represent an interesting class of modern Pharmaceuticals which with their low immunogenic potential mimic extend many of the properties of monoclonal antibodies in diagnostics, research, and therapeutics. More recently, chimeric aptamer approach employing many different possible types of chimerization strategies has generated more stable and efficient chimeric aptamers with aptamer-aptamer, aptamer-nonaptamer biomacromolecules (siRNAs, proteins) and aptamer-nanoparticle chimeras. These chimeric aptamers when conjugated with various biomacromolecules like locked nucleic acid (LNA) to potentiate their stability, biodistribution, and targeting efficiency, have facilitated the accurate targeting in preclinical trials. We developed LNA-aptamer (anti-nucleolin and EpCAM) complexes which were loaded in iron-saturated bovine lactofeerin (Fe-blf)-coated dopamine modified surface of superparamagnetic iron oxide (Fe(3)O(4)) nanoparticles (SPIONs). This complex was used to deliver the specific aptamers in tumor cells in a co-culture model of normal and cancer cells. This review focuses on the chimeric aptamers, currently in development that are likely to find future practical applications in concert with other therapeutic molecules and modalities. |
format | Online Article Text |
id | pubmed-3233271 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Informa Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-32332712011-12-08 Chimeric aptamers in cancer cell-targeted drug delivery Kanwar, Jagat R Roy, Kislay Kanwar, Rupinder K Crit Rev Biochem Mol Biol Review Article Aptamers are single-stranded structured oligonucleotides (DNA or RNA) that can bind to a wide range of targets ("apatopes") with high affinity and specificity. These nucleic acid ligands, generated from pools of random-sequence by an in vitro selection process referred to as systematic evolution of ligands by exponential enrichment (SELEX), have now been identified as excellent tools for chemical biology, therapeutic delivery, diagnosis, research, and monitoring therapy in real-time imaging. Today, aptamers represent an interesting class of modern Pharmaceuticals which with their low immunogenic potential mimic extend many of the properties of monoclonal antibodies in diagnostics, research, and therapeutics. More recently, chimeric aptamer approach employing many different possible types of chimerization strategies has generated more stable and efficient chimeric aptamers with aptamer-aptamer, aptamer-nonaptamer biomacromolecules (siRNAs, proteins) and aptamer-nanoparticle chimeras. These chimeric aptamers when conjugated with various biomacromolecules like locked nucleic acid (LNA) to potentiate their stability, biodistribution, and targeting efficiency, have facilitated the accurate targeting in preclinical trials. We developed LNA-aptamer (anti-nucleolin and EpCAM) complexes which were loaded in iron-saturated bovine lactofeerin (Fe-blf)-coated dopamine modified surface of superparamagnetic iron oxide (Fe(3)O(4)) nanoparticles (SPIONs). This complex was used to deliver the specific aptamers in tumor cells in a co-culture model of normal and cancer cells. This review focuses on the chimeric aptamers, currently in development that are likely to find future practical applications in concert with other therapeutic molecules and modalities. Informa Healthcare 2011-12 2011-09-28 /pmc/articles/PMC3233271/ /pubmed/21955150 http://dx.doi.org/10.3109/10409238.2011.614592 Text en © 2011 Informa Healthcare USA, Inc http://creativecommons.org/licenses/by/2.0/ This is an open access article distributed under the Supplemental Terms and Conditions for iOpenAccess articles published in Informa Healthcare journals (http://www.informaworld.com/mpp/uploads/iopenaccess_tcs.pdf) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Kanwar, Jagat R Roy, Kislay Kanwar, Rupinder K Chimeric aptamers in cancer cell-targeted drug delivery |
title | Chimeric aptamers in cancer cell-targeted drug delivery |
title_full | Chimeric aptamers in cancer cell-targeted drug delivery |
title_fullStr | Chimeric aptamers in cancer cell-targeted drug delivery |
title_full_unstemmed | Chimeric aptamers in cancer cell-targeted drug delivery |
title_short | Chimeric aptamers in cancer cell-targeted drug delivery |
title_sort | chimeric aptamers in cancer cell-targeted drug delivery |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3233271/ https://www.ncbi.nlm.nih.gov/pubmed/21955150 http://dx.doi.org/10.3109/10409238.2011.614592 |
work_keys_str_mv | AT kanwarjagatr chimericaptamersincancercelltargeteddrugdelivery AT roykislay chimericaptamersincancercelltargeteddrugdelivery AT kanwarrupinderk chimericaptamersincancercelltargeteddrugdelivery |